insulin detemir vs Insulin glargine (Toujeo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin detemir · Levemir
Rights held by Novo Nordisk; US product discontinued
NCT00283751 · Phase 3 · completed
The study randomized 583 participants to insulin detemir or insulin glargine, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00856986
Insulin glargine (Toujeo)
Marketed by Sanofi
NCT01499082 · Phase 3 · completed
The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.
Reported efficacy
Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)
Result source: NCT01499082
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin detemir | Insulin glargine (Toujeo) |
|---|---|---|
| HbA1c, change | -0.5% vs 0.0%vs Lira 1.8NCT008569866 other results
| —Not reported |
| Body weight, change (kg) | 3.6 vs 6.4vs Insulin AspartNCT001846008 other results
| —Not reported |
| HbA1c below 7% | —Not posted · NCT00604396 | —Not reported |
| Fasting plasma glucose, change | -1.9 vs -0.1vs Lira 1.8NCT008569862 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT00604396 | —Not reported |
HbA1c, change
- insulin detemir
- -0.5% vs 0.0%vs Lira 1.8NCT00856986
6 other results
- -0.5% vs -0.1% NCT00856986
- -0.5% vs 0.0% NCT00856986
- -1.0% vs -1.1% NCT01165684
- -0.5% vs -0.7% NCT00909480
- -0.8% vs -1.1% NCT01165684
- -0.5% vs -1% NCT01165684
- Insulin glargine (Toujeo)
- —Not reported
Body weight, change (kg)
- insulin detemir
- 3.6 vs 6.4vs Insulin AspartNCT00184600
8 other results
- -0.1 vs -1.0 NCT00856986
- 1.9 vs 5.7 NCT00184600
- -0.2 vs -0.9 NCT00856986
- -0.8 vs -1.7 NCT00789191
- -0.5 vs 1 NCT00909480
- 0.3 vs 0.8 NCT00998335
- 13 vs 12.6 NCT01837680
- 1.2 vs 2.8 NCT00604396
- Insulin glargine (Toujeo)
- —Not reported
HbA1c below 7%
- insulin detemir
- —Not posted · NCT00604396
- Insulin glargine (Toujeo)
- —Not reported
Fasting plasma glucose, change
- insulin detemir
- -1.9 vs -0.1vs Lira 1.8NCT00856986
2 other results
- -2.1 vs -0.4 NCT00856986
- 6.4 vs 4.9 NCT00998335
- Insulin glargine (Toujeo)
- —Not reported
3-point MACE (% with event)
- insulin detemir
- —Not posted · NCT00604396
- Insulin glargine (Toujeo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. insulin detemir: 6 of 6 rows · Insulin glargine (Toujeo): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin detemir | Insulin glargine (Toujeo) |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -3.89 mmol/L @ 20wk*a,b,c,d NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -70 mg/dL as posted show 1 more dose-3.35 mmol/L @ 20wk* NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -60.4 mg/dL as posted | -2.66 mmol/L @ 52wk*b,c,d NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48 mg/dL as posted |
| HbA1c absolute change · percentage points No placebo or comparator arm | -1% (n=21) @ 20wka,b,c,d NCT01868542 · Phase 4 · registry result, not featured evidence show 1 more dose-0.9% (n=23) @ 20wk NCT01868542 · Phase 4 · registry result, not featured evidence | -1.29% (n=1651) @ 52wkb,c,d NCT02451137 · Phase 4 · registry result, not featured evidence |
| Dropout rate | 0%e NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results8.7%Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence 0%Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 13.9% NCT01165684 · Phase 4 · registry result, not featured evidence 16.7% NCT00909480 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 6.9% NCT00455858 · Phase 4 · registry result, not featured evidence 12.3%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 14.8%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination 0% NCT00590226 · Phase 4 · registry result, not featured evidence · combination 19.2% NCT00184600 · Phase 3 · registry result, not featured evidence 12.6% NCT00789191 · Phase 3 · registry result, not featured evidence · combination 0%Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence 18.2%Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination 15.1% NCT01837680 · Phase na · registry result, not featured evidence | 14.8%f NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result14.9% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 0%e NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results—Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence —Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 0.5% NCT01165684 · Phase 4 · registry result, not featured evidence 2.2% NCT00909480 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination — NCT00591227 · Phase 4 · registry result, not featured evidence — NCT00455858 · Phase 4 · registry result, not featured evidence 1.6%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 2.5%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination — NCT00590226 · Phase 4 · registry result, not featured evidence · combination 3.8% NCT00184600 · Phase 3 · registry result, not featured evidence 1.8% NCT00789191 · Phase 3 · registry result, not featured evidence · combination —Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence —Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination — NCT01837680 · Phase na · registry result, not featured evidence | —f NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result2.6% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 10.4%e NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results4.3%Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence 0%Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 9.1% NCT01165684 · Phase 4 · registry result, not featured evidence 3.1% NCT00909480 · Phase 4 · registry result, not featured evidence 0% NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 5.7% NCT00455858 · Phase 4 · registry result, not featured evidence 4.1%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 3.3%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 0% NCT00467649 · Phase 4 · registry result, not featured evidence · combination 22.4% NCT00590226 · Phase 4 · registry result, not featured evidence · combination 33.3% NCT00184600 · Phase 3 · registry result, not featured evidence 1.9% NCT00789191 · Phase 3 · registry result, not featured evidence · combination 0%Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence 0%Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination 0% NCT01837680 · Phase na · registry result, not featured evidence | 19.4%f NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result9.8% NCT02451137 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | e nasopharyngitis 20.2% nausea 18.4% diarrhoea 17.8% NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 13 more resultsnasopharyngitis 13% headache 8.7% upper respiratory tract infection 4.3% NCT01868542 · Phase 4 · registry result, not featured evidence nasopharyngitis 13% rash 8.7% upper respiratory tract infection 8.7% NCT01868542 · Phase 4 · registry result, not featured evidence nasopharyngitis 8.1% headache 5.1% influenza 5.1% NCT01165684 · Phase 4 · registry result, not featured evidence nasopharyngitis 10.6% upper respiratory tract infection 8% headache 7.5% NCT00909480 · Phase 4 · registry result, not featured evidence nasopharyngitis 11.5% upper respiratory tract infection 5.7% NCT00455858 · Phase 4 · registry result, not featured evidence back pain 5.8% headache 5% upper respiratory tract infection 5% NCT00634842 · Phase 4 · registry result, not featured evidence pain in extremity 3.3% urinary tract infection 3.3% anxiety 2.5% NCT00634842 · Phase 4 · registry result, not featured evidence nausea 11.1% diarrhoea 5.6% hypertension 5.6% NCT00467649 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 46.2% diarrhoea 25.6% infection 21.4% NCT00184600 · Phase 3 · registry result, not featured evidence headache 14.5% nasopharyngitis 13.2% back pain 10.5% NCT00789191 · Phase 3 · registry result, not featured evidence · combination gastrointestinal intolerance 0% NCT01232946 · Phase na · registry result, not featured evidence gastrointestinal intolerance 18.2% NCT01232946 · Phase na · registry result, not featured evidence · combination biochemical event of hypoglycemia 50.9% symptomatic hypoglycemia 30.2% symptomatic nocturnal event 15.1% NCT01837680 · Phase na · registry result, not featured evidence | f trauma 3.7% cough 0.9% gastroparesis 0.9% NCT03013985 · Phase 4 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 20 weeks versus 52 weeks.
- ePopulation comparability has not been reviewed for 16 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin detemir
show 6 more results
show 3 more results
show 9 more results
show 2 more results
show 5 more results
show 2 more results
+ 34 further endpoints in the CSV export.
Insulin glargine (Toujeo)
show 6 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin detemir's landscape · Insulin glargine (Toujeo)'s landscape